Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age.

Autor: Ong-Lim AL; Philippine General Hospital, University of the Philippines Manila, Manila, Philippines., Shukarev G; Janssen Vaccines AG, Bern, Switzerland., Trinidad-Aseron M; De La Salle University Medical Center, Cavite, Philippines., Caparas-Yu D; De La Salle Medical and Health Sciences Institute, Cavite, Philippines., Greijer A; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands., Duchene M; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands., Scheper G; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands., van Paassen V; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands., Le Gars M; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands., Cahill CP; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands., Schuitemaker H; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands., Douoguih M; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands., Jacquet JM; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.

Publikováno v: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2022 Nov 30; Vol. 18 (5), pp. 2044255. Date of Electronic Publication: 2022 Mar 28.